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Objectives. The present study aimed to explore the effect of resistance training in patients with amyotrophic lateral sclerosis (ALS),
a disease characterized by progressive motor neuron loss and muscle weakness. Materials and Methods. Following a 12-week
“lead-in” control period, a population of ALS patients from Funen, Denmark, completed a 12-week resistance training program
consisting of 2-3 sessions/week. Neuromuscular function (strength and power) and voluntary muscle activation (superimposed
twitch technique) were evaluated before and after both control and training periods. Physical capacity tests (chair rise and timed up
and go), the revised ALS functional rating scale (ALSFRS-R) scores, and muscle cross sectional area (histology) were also assessed.
Results. Of twelve ALS patients assessed for eligibility, six were included and five completed the study. Training did not significantly
affect the ALSFRS-R score, and loss of neuromuscular function (strength and power) increased following the training period.
However, an improved functionality (chair rise) and an increase in greatly hypertrophied type II fibres combined with an increase
in atrophied fibres following the training period compared to the control period were observed. Conclusion. In this small study,
the present form of resistance training was unable to attenuate progressive loss of neuromuscular function in ALS, despite some
changes in physical capacity and morphology.
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurode-
generative disease affectingmotor neurons in the spinal cord,
brain stem, and motor cortex, resulting in muscle weakness
and atrophy and eventually death [1].
In young as well as old healthy individuals resistance
training appears highly effective for reducing muscle weak-
ness and improving neuromuscular function (i.e., inducing
gains in skeletal muscle strength and power) [2–4]. His-
torically, exercise in ALS has been thought to exacerbate
muscle weakness, increase fatigue, and accelerate disease
progression [5]. However, recent studies in ALS mice and
patients—although limited in number—have challenged this
view. In addition to an early case report showing positive
effects of resistance training in ALS patients [6], it was
first reported that exercise could improve the clinical course
(Spinal Norris scores) and the performance in respiratory
functional tests following exercise [7, 8]. Very recently it
was reported in a randomized controlled trial that 6 months
combined resistance and aerobic training led to improve-
ments in the revised ALSFRS (ALS functional rating scale)
[9]. Other observations in small cohorts include improved
ALSFRS scores, quality of life, and maximal muscle strength
measured by the QuantitativeMuscle Assessment system fol-
lowing three months combined resistance type and flexibility
training [10] and improved ALSFRS and decreased muscle
spasticity following threemonths resistance type training [11].
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Spinal motor neuron death results in partial denervation
of skeletal muscle and is accompanied by sprouting and rein-
nervation, which in turn increase the size of the remaining
motor units (MUs) [12].The loss ofMUs has been reported to
half in each 6-month period during the first year in ALS,
hereafter diminishing more slowly [13]. In addition, remain-
ing MUs seem less efficient and fatigue more easily in ALS
patients compared to healthy age-matched controls [14].
While this loss of MUs may likely have a negative effect on
neuromuscular function, exercisemay be able to diminish the
loss of MUs and thus partly preserve neuromuscular func-
tion. Another important aspect of neuromuscular function
relate to voluntary muscle activation, which yields a percent-
age measure of the neural input that reaches a given muscle
[4].
It is still debated whether resistance training promotes or
prevents progression of motor neuron degeneration in ALS.
With this exploratory study we wanted to add to the existing
knowledge by applying evaluation methods typically used in
classical exercise science including measures of neuromus-
cular function (e.g., muscle strength) and voluntary muscle
activation, which all remain unknown in ALS.
Therefore, the aim of this study was to explore the effect
of resistance training on the ALSFRS-R as well as by evalu-
ating voluntary muscle activation, neuromuscular function,
histology, and functionality in ALS patients, as these evalu-
ation methods could potentially serve as valuable endpoints
when conducting larger training studies.
2. Methods
2.1. Study Design. The study is an open-label trial using a
repeated measures design consisting of a 12-week “lead-in
period” to benchmark individual disease progression (con-
trol period) followed by a 12-week resistance training inter-
vention (training period). Information on the study design
and data describing histopathological changes due to natural
disease progression during the control period have previously
been published [15].
Test and training was performed at the Department of
Sports Science and Clinical Biomechanics at the University
of Southern Denmark and Odense University Hospital. The
control period served as a basis for estimating individual
disease progression assuming a variable, yet linear decline in
motor function over the 24-week study period, as this has pre-
viously been found to be a good approximation [16, 17]. We
acknowledge that this is an assumption, but for the explora-
tory purposes of the study and the novel application of eval-
uation methods, we consider it reasonable.
Assessment of physical capacity, neuromuscular function,
voluntary muscle activation, and skeletal muscle biopsies
were collected at baseline (BL, 𝑇 = 0wks) and before (Pre,
𝑇 = 12wks) and after (Post, 𝑇 = 24wks) the training inter-
vention. Data were obtained from the leg that was weakest at
baseline. Participants were familiarized with all tests prior to
performing baseline measures to minimize learning effects.
Participants were informed of risks associated with the
study and provided written, informed consent before inclu-
sion. The study was performed according to the Declaration
ofHelsinki andwas approved by the local ethics committee of
the Region of Southern Denmark (S-20100116). The trial was
registered at clinicaltrials.gov (ID: NCT01504009).
2.2. Subjects. Six patients (aged 62.5 ± 8.8 years) diagnosed
with amyotrophic lateral sclerosis (ALS) met the inclusion
criteria and volunteered to participate in the study (Table 1).
Inclusion criteria were diagnosis of definite or probable ALS
based on the El Escorial criteria, ambulatory at onset of study,
and being able to travel to training and test centre. Exclusions
criteria were neurological or other serious medical problems
and noncompliance with study protocol. At the time of inclu-
sion all patients were able to walk unassisted. See [15] for
further participant details.
2.3. Sample Size. The present study utilises patients sampled
from one population (the island Funen, Denmark), and as
such they are representative of the ALS population in general.
The evaluation methods are not commonly used with ALS
patients, which made it difficult to estimate the minimal
clinically relevant effect and furthermoremade it inapplicable
to perform a power calculation prior to the study.
2.4. Resistance Training Intervention. The exercise protocol
consisted of resistance exercise performed onnonconsecutive
days 2-3 times per week. Exercises targeting both the upper
and lower body (leg press, knee extension, leg curl, calf raises,
lateral arm pull, seated rows, chest press, shoulder press,
abdominal crunches, and back extension) were included in
an alternating program utilising 6 exercises each session.
Training was performed in small groups supervised by two
experienced physical trainers and each session was initiated
with a 5min warm-up on a stationary bike (50–100watts).
The initial two weeks were used as familiarization with 3 sets
of 12 repetitions at 15-repetition maximum (RM) load, and
hereafter the training load progressed throughout the study
concludingwith 2 sets of 5 repetitions at 6 RM (by use of 5 RM
testing). Continuous adjustments in exercises were made to
ensure optimal compliance, as some exercises became dif-
ficult to perform due to individual disease progressions.
Within 15min after each training session protein supplemen-
tation was provided to all subjects (24 EN%, 18 g protein,
Nutridrink, Nutricia, Denmark).
2.5. Functional Evaluation. Experienced health personnel
evaluated functional ability by use of (i) the revisedALS func-
tional rating scale (ALSFRS-R) questionnaire [18], (ii) 30 s
chair rise (number of chair stands performed in 30 seconds)
[19], and (iii) the timed up and go (TUG) [20].
2.6. Neuromuscular Function. For evaluation of maximal
knee extensor strength, handgrip strength, and plantar flexor
strength (elaborated below) subjects were instructed to con-
tract as fast and forcefully as possible for 3-4 seconds during
each trial. A minimum of 3 trials was performed for each
interspersed by 1min rest intervals. Also, verbal motivation
and online visual feedback were provided.
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Table 1: Clinical characteristics of the participants at baseline. Subject 6 left the study by the end of the control period and is thus excluded
from all data calculations except this table.
Subject 1 2 3 4 5 6 Mean
Age (years) 68 47 65 69 57 69 62.2 ± 8.2
Sex Female Male Male Male Male Male N/A
Disease duration (months) <12 <12 <12 180 <12 <12 N/A
Site of onset Spinal Spinal Bulbar Spinal Spinal Bulbar N/A
ALSFRS-R 42 40 38 38 43 37 39.7 ± 2.4
Riluzole treatment − − − − + − N/A
Height (cm) 164 176 178 169 182 171 173 ± 6.0
Weight (kg) 62 74 67 79 85 82 74.8 ± 8.2
2.6.1. Maximal Knee Extensor Strength. Maximal isometric
strength of the knee extensor muscles was evaluated by use of
an isokinetic dynamometer (Kin-Com,Chattecx,USA) [3, 4],
as previously described in detail [4].The trial with the highest
moment of force was selected and presented in absolute
values (Nm).
2.6.2. Handgrip Strength. Maximal isometric strength of the
handgrip muscles was evaluated by use of a custom-build
dynamometer setup. Subjects were standing with their arms
fully extended gripping around the dynamometer (adjusted
to individual finger length). Force data were sampled, anal-
ysed, and presented in N.
2.6.3. Plantar Flexor Strength. Maximal isometric muscle
strength of the plantar flexor muscles was evaluated by use
of a custom-built dynamometer setup (Kistler piezoelectric
force transducer [2]). Subjects were seated with their leg fully
extended (adjusted individually) and a 5∘ dorsal flexion in
their ankle joint. Force data were sampled, analysed, and
presented in N.
2.6.4. Leg Extension Power. Unilateral lower limb muscle
power was evaluated using the Nottingham leg extensor
power rig [21]. Participants were seated in the power-rig chair
(adjusted to individual leg length, 20∘ knee joint angle at full
extension), while pushing the footplate connected to a fly-
wheel as hard and fast as possible. Aminimumof 5 trials with
visual feedback was performed.The highest trial is presented
in absolute values (W).
2.6.5. Voluntary Muscle Activation. Maximal voluntary mus-
cle activation (neural drive) of the knee extensor muscles was
evaluated by use of the superimposed twitch technique, as
previously described [4]. Voluntary muscle activation was
calculated as the ratio between two doublet twitch stimu-
lation amplitudes, that is, the superimposed force response
elicited during maximal knee extension expressed relative to
the force response measured during the subsequent muscle
resting phase. The trial with the highest activation is pre-
sented in percentage of maximal muscle activation (%).
2.7. Muscle Biopsy Sampling and Immunohistochemistry.
Muscle biopsieswere collectedwith a 5mmBergstro¨mneedle
fromm. vastus lateralis under local anaesthetic (1% lidocaine;
Amgros, Denmark). First myosin heavy chain isoform one
(MHC-I) (1 : 2000, M8421, Sigma-Aldrich) and thenMHC-II
(1 : 2000, M4276, Sigma-Aldrich) were detected by standard
immunohistochemistry (Vector Laboratories, Denmark).
Analyses were performed using Axio imager M1 and Axio
Vision by Zeiss (Brock &Michelsen, Denmark).The percent-
age of type I and II fibres, the cross sectional area (CSA),
and the percentage of fibres in each of three groups (“Small-
sized fibres”: CSA= 0–2999 𝜇m2, “normal-size fibres”: CSA=
3000–9900𝜇m2, and “large-sized fibres”: CSA > 10.000𝜇m2)
were determined including all fibres from each patient
(85–651 fibres/biopsy). We defined “large-sized” fibres as
being >10.000 𝜇m2, since this is at least twice the size of
healthy, age-matched fibres [22].
2.8. Data Presentation and Statistical Analysis. Data are
reported as mean ± SD unless otherwise stated. Data in
Figure 2 are presented as the change during the control period
and the training period, respectively. Statistical significance
was tested with a paired 𝑡-test. For the histochemical analysis
of CSA, differences between BL, Pre, and Post were tested
with repeated measures two-way ANOVA followed by Bon-
ferroni post hoc testing. Asterisks indicate ∗𝑝 < 0.05.
3. Results
A flow chart describing participant numbers is shown in
Figure 1, and baseline characteristics are presented in Table 1.
One patient left the study by the end of the control period due
to percutaneous endoscopic gastrostomy (PEG) surgery and
is thus excluded from all data calculations. Three of the par-
ticipants completed 85–95% of all planned training sessions,
while the remaining two participants completed 50–60% of
training sessions due to medical problems not related to the
exercise program (intramuscular tumour involving surgery
and breathing difficulties due to muscle weakness resulting
in a collapse of the back).
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Control period 
Training period 
Assessed for eligibility 
(n = 12)
Included in the study 
(n = 6)
Completed the control period 
and evaluation 
(n = 5)
Participated in exercise program 
and nal evaluation 
(n = 5)
Withdrew due to PEG tube
(n = 1)
Did not meet inclusion criteria: 
(i) Unable to travel for training
sessions (n = 1)
(ii) Unable to walk (n = 5)
Figure 1: Study flow chart. Participant numbers and withdrawals
during the study are listed.
3.1. The Revised ALS Functional Rating Scale. Mean total
ALSFRS-R scores were 40.2 ± 2.3 versus 38.6 ± 1.9 versus
35.2 ± 4.3 at BL, Pre, and Post, respectively. ALSFRS-R scores
decreased to the same extent during control and training
periods in two participants, while they decreased more in
training versus control period in three participants (Fig-
ure 2(a)).
3.2. Functional Measures. The mean number of chair rises
was 9.6 ± 2.9 at baseline, 8.4 ± 3.8 at Pre, and 10.4 ± 6.5 at
Post. The mean time for completing the TUG was 15.9 ± 5.9
versus 17.9 ± 6.9 versus 17.8 ± 6.8 seconds at BL, Pre, and
Post, respectively. Figures 2(b) and 2(c) show the individual
% change following control and training periods. Generally,
the participants improved their performance in chair rise fol-
lowing the training period (𝑝 < 0.06), while two individuals
improved and two individuals worsened in TUG following
the training period.
3.3. Neuromuscular Function (Strength and Power). Neuro-
muscular function was evaluated by use of well-known tests
of strength and power (Table 2). Generally, participants per-
formed differently depending on individual muscle involve-
ment and disease progression. The individual percentage
change demonstrates an overall higher decrease in strength
during the training period compared to the control period,
which was significant (𝑝 < 0.05) for knee extensor, handgrip,
and leg extensor strength (Figures 2(d)–2(g)).
3.4. Voluntary Muscle Activation. As an indicator of the neu-
ral drive to the knee extensor muscles, voluntary muscle acti-
vation was evaluated by use of the superimposed twitch tech-
nique. Voluntary muscle activation was 96.1 ± 5.3% versus
93.5 ± 6.5% versus 93.4 ± 4.5% at BL, Pre, and Post, respec-
tively. Four of the five subjects hadmaximal voluntarymuscle
activation (>95%) when initiating the study. Yet, two out of
five participants increased their voluntary muscle activation
during training, and two had smaller decreases compared to
control period (Figure 2(h)).
3.5. Muscle Fibre Morphology. Muscle fibre type composition
(type I versus type II) did not change through the study
(Table 3). Muscle fibres ranged from less than 100 𝜇m2 to
more than 18.000 𝜇m2 (Figures 3(a)–3(d)), with the same
muscle sample often including both atrophied and hypertro-
phied fibres. The average CSA did not change between time
points (type I fibres: 3480 ± 336 𝜇m2 versus 3117 ± 670𝜇m2
versus 3567 ± 922𝜇m2, resp.; type II fibres: 3998 ± 528𝜇m2
versus 3461± 1011 𝜇m2 versus 3393± 1517 𝜇m2, resp.).Theper-
centage of small-sized type II fibres (representing atrophied
fibres) was larger at Pre and Post compared to BL (𝑝 < 0.05)
(Table 3). Also, the percentage of large fibres was higher at
Post compared to BL (𝑝 < 0.05). Consequently, percentage of
normal-sized fibres was smaller at Pre and Post compared to
BL.
4. Discussion
Since little information can be found in the literature about
the neuromuscular effects of resistance training in ALS
patients, this study explored the effect of resistance training
on neuromuscular function and voluntary muscle activation
in this patient group. In addition, the concurrent effect of
resistance training on skeletal muscle morphology was eval-
uated.
The main finding was that resistance training did not
attenuate the decline in ALSFRS-R, a finding that was
also supported by our results on neuromuscular function
(strength and power). However, our observations on func-
tionality, voluntary muscle activation, and CSA indicate that
resistance training was able to affect the skeletal muscle.
The present study found a mean decline on the revised
ALSFRS of 1.6 points during the control period and of 3.4
points during the training period. A previous study has
reported ALSFRS-R to decline 0.92 ± 0.08 points per month
[23], which is in line with our data (overall decline: 0.83 ±
0.64 points per month). The same study suggests a change of
20% or greater in the slope of the ALSFRS-R to be clinically
meaningful [23], indicating that the resistance training in our
study had no attenuating effect; rather it might have had a
worsening effect.This observation differs from three previous
studies, reporting positive effects onALSFRS-R scores follow-
ing resistance training using different regimes [9–11]. In one
of these studies the training period was 6 months rather than
12 weeks as in our study. If we had extended the training
period accordingly this may have changed the results. How-
ever, considering that our patients after 3 months of training
Journal of Neurodegenerative Diseases 5
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Figure 2: Functional performance andneuromuscular function. (a) Individual change in total scores of the revisedALS functional rating scale
(ALSFRS-R). Changes in functional performance in (b) chair rise and (c) timed up and go (TUG) during control and training periods. Note
that one participant was unable to perform chair rise at Pre and Post as well as TUG at Post; thus these data are excluded. Change in maximal
voluntarymuscle strength (MVC) of (d) knee extensors, (e) handgrip, and (f) plantar flexor during the control and training period. (g) Change
in explosive leg extension power. (h) Voluntary muscle activation measured by doublet twitch stimulations. Dots represent individual values
of change from BL to Pre (control period) and from Pre to Post (training period).
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BL
(a)
Pre
(b)
Post
(c)
Control
(d)
Figure 3: Muscle morphology. (a–d) Representative images of the histochemical staining of type I (blue) and type II fibres (red) from BL,
Pre, and Post. A healthy age-matched control is included as a reference. Scale bar = 100 𝜇m.
Table 2: Mean values of strength and power measures.
Evaluation method 𝑛 = 5 Baseline Pre Post
Knee extensor strength Nm 59.6 ± 31.1 54.6 ± 38.2 46.9 ± 41.1
Hand grip strength N 199.8 ± 87.5 226.6 ± 95.0 142.6 ± 55.4
Plantar flex N 59.9 ± 38.5 69.8 ± 44.4 51.9 ± 30.1
Leg power W 93.0 ± 65.1 101.9 ± 59.0 62.3 ± 44.0
Table 3: Muscle fibre morphology.
Total fibres Small fibres Normal fibres Large fibres
Type I fibres (%)
Baseline 52.5 ± 6.3 54.1 ± 3.0 43.6 ± 1.4 2.3 ± 0.32
Pre 54.9 ± 9.3 58.2 ± 6.1 39.5 ± 2.9 2.3 ± 0.37
Post 62.7 ± 14.5 56.5 ± 7.6 36.2 ± 2.6 7.4 ± 0.94
Type II fibres (%)
Baseline 42.7 ± 6.7 44.6 ± 3.6 51.6 ± 1.6 3.8 ± 0.40
Pre 40.3 ± 7.5 58.3 ± 7.1a 35.6 ± 2.3a 6.0 ± 0.78
Post 35.3 ± 9.0 63.3 ± 9.1a 23.9 ± 1.7a,b 12.8 ± 2.3a
Morphological analysis of fibre type composition (total type I fibres and total type II fibres) and cross-sectional area (CSA) defined as “small-sized fibres” (CSA
0–2999 𝜇m2), “normal-size fibres” (CSA 3000–9900 𝜇m2), and “large-sized fibres” (CSA > 10.000𝜇m2). a denotes differences from baseline and b denotes
difference from pre; 𝑝 < 0.05.
showed no neuromuscular functional improvement, it is
most unlikely that extending the training period would have
benefitted the patients.
Generally we observed an increased loss of muscle
strength (knee extensor, handgrip, and plantar flexor) and
power during the training versus the control period. Since all
participants were familiarized with the different tests, these
results were unlikely due to a learning effect. Previous studies
using progressive resistance training programs similar to the
present have proven effective in improving muscle strength
and functionality in frail older individuals [2, 4, 24]. Resist-
ance training interventions in ALS patients reporting positive
results have used individualized moderate-intense exercises
yet without providing more specific details on the exercises,
intensity, progression, and so on [6, 9–11]. These aspects
probably explain someof the discrepancy in previous findings
compared to the present findings, along with the heterogene-
ity and size of the ALS study populations. In our small cohort
of patients, one of the subjects had a very slowly developing
form of ALS. It could be considered that inclusion of this
subject may have biased the results; however, if we remove
this patient from our analyses, it does not change the out-
come; thus all analyses presented here include all 5 subjects.
Others aspects such as the interactions between signalling
pathways for protein synthesis and protein degradation could
also have played a role and would be worth investigating in
future studies.
Voluntary muscle activation has been shown to improve
in older individuals following resistance training [4], which
is in line with our findings of a diminished decrease after the
training period versus the control period. The level of volun-
tary muscle activation was generally very high, making little
room for improvements as previously shown [4]. It is the
general view that when spinalmotor neurons die, the remain-
ing motor neurons become exposed to an increased work
demand in order to compensate and produce the samemuscle
forces required to perform activities of daily living. One sub-
ject was diagnosed with ALS 15 years prior to inclusion in the
study (i.e., having slowly progressing ALS) and was the one
having a low level of voluntary muscle activation at baseline.
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It is likely that physical inactivity and disuse may have taken
part in reducing the voluntary muscle activation level as
previously shown in the aging population.
The latter point is of significance in relation to applying
resistance training for ALS patients. If a person—with or
without ALS—is physically inactive, loss of neuromuscular
function will inevitably occur, subsequently leading to a
progressive loss of physical capacity. Hence, a combination
of disuse- and disease-induced muscle weakness might cause
additional detrimental effects in ALS patients.
Muscle disuse and sarcopenia leads to a reduced fibre
CSA, while resistance training has the opposite effect eliciting
increases in CSA in young and old people [22]. Particularly
hypertrophy of type II fibres is seen as a compensatory
mechanism and is also seen in overloaded skeletal muscle of
patients with neuromuscular diseases such as ALS [25].
The increase in the percentage of “small-sized” type II
fibres with time was accompanied by an increase in “large-
sized” type II fibres at Post and a concurrent decrease in
“normal-sized” fibres. While the hypertrophy of single fibres
may have been a result of compensatory MU “overload” dur-
ing resistance training (i.e., indicating a morphological train-
ing effect), it may also be due to disease progression in itself.
In any case these changes in fibre size distribution apparently
were unable to compensate for the disease-induced progres-
sive loss of motor neurons, which contributed to the contin-
uous decrease in neuromuscular function.
The participants received protein supplements after each
training session to ensure proper nutritional status; however
issues of tissue oxygenation and potential hypoxia were not
investigated in the present study and might have played a
role in attenuating the hypertrophic response [26]. Oxygen
capacity could be investigated in a future study.
The present study holds some limitations.Themost obvi-
ous is the small number of patients included in the stury
and their heterogeneous disease progression. However as the
participants represent an entire population of ALS patients
from Funen, Denmark, we may be able to generalise our
findings to larger populations of ALS patients. As for the
study design, we chose a study design with a “lead-in” control
period to take into account the individual disease progres-
sion, rather than a case-control design.The ladderwould have
required a highly effective paring in regard to sex, age, and
disease progression between controls and exercisers. We did
not find it reasonable to perform a large-scale randomized
controlled trial (RCT) before the applied methods had been
tested in a small-scale study. Yet, a major strength of the
present study is the longitudinal collection of functional and
neuromuscular performance data combined with concurrent
muscle biopsy sampling, which is unique in ALS patients
and it is our hope that the present findings can serve as a
background for planning future studies.
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